Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Pemetrexed (used as a platinum doublet or as a maintenance regimen) is an established therapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). In addition, certain gene rearrangements (e.g., ALK, ROS1, RET) appear to especially benefit from the use of pemetrexed. Inferior...

Full description

Bibliographic Details
Main Authors: Tejas Patil, Yunan Nie, Dara L. Aisner, David Ross Camidge
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
ALK
ROS1
non-small-cell lung cancer
pemetrexed
squamous
adenosquamous
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.788245/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.788245/full

Similar Items